FGFR3 | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Conferences Trial results

25 October 2024

Triple meeting 2024 – Tyra’s targeted FGFR3 push

The company reckons it’s got what it takes to hit the right member of the FGFR family.

Subscribe to FGFR3